Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: Description of a novel modular targeting system

Leukemia

Volumn 28, Issue 1, 2014, Pages 59-69

  Arndt, C ^a   Feldmann, A ^a,b   Von Bonin, M ^c   Cartellieri, M ^a   Ewen, E M ^a   Koristka, S ^a   Michalk, I ^a   Stamova, S ^a   Berndt, N ^a   Gocht, A ^a   Bornhauser M ^c   Ehninger, G ^c   Schmitz, M ^a,d   Bachmann, M ^a,b,d  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

acute myeloid leukemia; CD33; costimulatory immunoligands; immunotherapy; single chain bispecific antibodies; T cell retargeting

Indexed keywords

BISPECIFIC ANTIBODY; CD137 LIGAND; CD33 ANTIGEN; CD33 ANTIGEN E5B9 FUSION PROTEIN; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CANCER IMMUNOTHERAPY; CELL INTERACTION; CELL KILLING; CELL STRAIN 3T3; CELL STRAIN HEK293; CHO CELL; CONTROLLED STUDY; DEGRANULATION; DRUG BINDING; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LEUKEMIA CELL LINE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE RETARGETING; TARGET CELL;

ANIMALS; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE ACTIVATION; MALE; SIALIC ACID BINDING IG-LIKE LECTIN 3; T-LYMPHOCYTES;

EID: 84891858752     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.243     Document Type: Article

References (39)

1. Müller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy: current perspectives. BioDrugs 2010; 24: 89-98.
2. Stamova S, Koristka S, Keil J, Arndt C, Feldmann A, Michalk I et al. Cancer immunotherapy by retargeting of immune effector cells via recombinant bispecific antibody constructs. Antibodies 2012; 1: 172-198.
3. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005; 115: 98-104. (Pubitemid 40559673)
4. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006; 43: 763-771. (Pubitemid 41785405)
5. Stamova S, Feldmann A, Cartellieri M, Arndt C, Koristka S, Apel F et al. Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses. Anal Biochem 2012; 423: 261-268.
6. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974-977.
7. Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cellengaging BiTE antibody blinatumomab. Exp Cell Res 2011; 317: 1255-1260.
8. Topp MS, Kufer P, Gö kbuget N, Goebeler M, Klinger M, Neumann S et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapyrefractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29: 2493-2498.
9. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012; 119: 6226-6233.
10. Feldmann A, Stamova S, Bippes CC, Bartsch H, Wehner R, Schmitz M et al. Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats. Prostate 2011; 71: 998-1011.
11. Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009; 31: 2349-2370.
12. Zhong RK, Lane TA, Ball ED. Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells. Exp Hematol 2008; 36: 486-494.
13. Draube A, Beyer M, Wolf J. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells. Eur J Haematol 2008; 81: 281-288.
14. Rezvani K, Yong AS, Tawab A, Jafarpour B, Eniafe R, Mielke S et al. Ex vivo characterization of polyclonal memory CD8\+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 2009; 113: 2245-2255.
15. Bornhäuser M, Thiede C, Platzbecker U, Kiani A, Oelschlaegel U, Babatz J et al. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. Blood 2011; 117: 7174-7184.
16. Stamova S, Cartellieri M, Feldmann A, Bippes CC, Bartsch H, Wehner R et al. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia 2011; 25: 1053-1056.
17. Aigner M, Feulner J, Schaffer S, Kischel R, Kufer P, Schneider K et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 2013; 27: 1107-1115.
18. Arndt C, von Bonin M, Cartellieri M, Feldmann A, Koristka S, Michalk I et al. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia 2013; 27: 964-967.
19. Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 1986; 67: 1048-1053. (Pubitemid 16116418)
20. Legrand O, Perrot JY, Baudard M, Cordier A, Lautier R, Simonin G et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 2000; 96: 870-877. (Pubitemid 30616850)
21. Feldmann A, Arndt C, Tö pfer K, Stamova S, Krone F, Cartellieri M et al. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8\+ and CD4\+ T cells. J Immunol 2012; 189: 3249-3259.
22. Stamova S, Cartellieri M, Feldmann A, Arndt C, Koristka S, Bartsch H et al. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. Mol Immunol 2011; 49: 474-482.
23. Koristka S, Cartellieri M, Arndt C, Bippes CC, Feldmann A, Michalk I et al. Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B. J Autoimmun 2013; 42: 105-116.
24. Koristka S, Cartellieri M, Theil A, Feldmann A, Arndt C, Stamova S et al. Retargeting of human regulatory T cells by single-chain bispecific antibodies. J Immunol 2012; 188: 1551-1558.
25. Carmo-Fonseca M, Pfeifer K, Schrö der HC, Vaz MF, Fonseca JE, Mü ller WE et al. Identification of La ribonucleoproteins as a component of interchromatin granules. Exp Cell Res 1989; 185: 73-85. (Pubitemid 19284956)
26. Dreier T, Baeuerle PA, Fichtner I, Grün M, Schlereth B, Lorenczewski G et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J Immunol 2003; 170: 4397-4402. (Pubitemid 36428210)
27. Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N et al. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother 2006; 55: 503-514.
28. Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E et al. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother 2009; 32: 341-352.
29. Amann M, D'Argouges S, Lorenczewski G, Brischwein K, Kischel R, Lutterbuese R et al. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother 2009; 32: 452-464.
30. Fortmüller K, Alt K, Gierschner D, Wolf P, Baum V, Freudenberg N et al. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA-CD3 bispecific single-chain diabody. Prostate 2011; 71: 588-596.
31. Berthon C, Driss V, Liu J, Kuranda K, Leleu X, Jouy N et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol Immunother 2010; 59: 1839-1849.
32. Ma Q, Wang C, Jones D, Quintanilla KE, Li D, Wang Y et al. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy 2010; 12: 1056-1062.
33. Hornig N, Kermer V, Frey K, Diebolder P, Kontermann RE, Mü ller D. Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. J Immunother 2012; 35: 418-429.
34. Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett 2006; 236: 229-238.
35. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013; 31: 71-75.
36. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002; 100: 690-697. (Pubitemid 34832980)
37. Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbü se R, Schlereth B et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 2009; 214: 441-453.
38. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23: 1126-1136. (Pubitemid 41486394)
39. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52: 3402-3408.